Here are four updates on GI companies from the past week:
Bausch Health and Salix Pharmaceuticals settled outstanding intellectual property claims against their drug Xifaxan from generic drugmaker Actavis Laboratories.
Bayer added a warning to its prescription-free stomach relief Iberogast drops after a patient died from the product.
The FDA awarded Motus GI's Pure-Vu Slim Sleeve 510(k) clearance, expanding Motus' reach to encompass the full range of gastrointestinal procedures.
Prescient Medicine Holdings and Metabiomics partnered to develop a microbiome diagnostic platform to diagnose gastrointestinal diseases including Crohn's disease, ulcerative colitis and irritable bowel syndrome.